3 Canadian Biotech Stocks With P E Under 12

Bond markets are screaming for attention right now, with long term government borrowing costs at their highest levels in decades. Expensive growth stories feel the pressure when money suddenly has a clear yield elsewhere. That is exactly when investors start hunting for Canadian biotech opportunities backed by reasonable balance sheets and grounded valuations. This article walks through three such biotech stocks picked from our screener.

The three stocks below are only a starting sample from this biotech idea. The full screen surfaced 5 more companies with equally compelling stories that are not covered here. To go broader and identify your own high conviction setups, head straight into the Biotech Stocks screener.

Auxly Cannabis Group (TSX:XLY)

Auxly Cannabis Group aligns with the Biotech Stocks theme through its cannabis based medical and consumer products, using cultivation, formulation and processing capabilities to turn plant science into packaged goods that reach patients and adult users across Canada.

Auxly Cannabis Group generates about CA$166 million from its cannabis focused venture capital segment in Canada and carries a market cap of roughly CA$373 million, placing it in small cap territory for investors considering biotech linked cannabis exposure.

For Auxly, the core biotech angle is less about lab driven drug discovery and more about how it scales cannabis derived formulations into branded products that can maintain shelf space and pricing power in a crowded legal market.

"Back Forty holding the position as the number one cannabis brand in Canada by dollars sold, with leading products in dried flower, pre rolls and vapes, gives Auxly brand scale in categories that are expected to remain core for adult use cannabis. This can support sustained net revenue growth and brand driven pricing power."

The key question now is how a quieter shift in cost structure will affect future margins if demand for these cannabis lines remains stable.

If that margin story is what you care about, the full narrative for Auxly Cannabis Group breaks down how Auxly Cannabis Group’s brand muscle and balance sheet could be quietly decoupling.

Bright Minds Biosciences (CNSX:DRUG)

Bright Minds Biosciences focuses on biotech drug development, working on serotonin based 5-HT2 receptor therapeutics such as BMB-101 for epilepsy and related neurological conditions, with other compounds in early stages and a market cap around CA$703 million as of late 2026.

Bright Minds Biosciences fits the Biotech Stocks screener because it is an early stage developer of serotonin based 5-HT2 therapies, led by BMB-101 in Phase 2 trials for difficult epileptic disorders, with a pipeline and EEG collaboration that could influence investor expectations.

That pipeline focus makes the analysis report for Bright Minds Biosciences a fast way to see how trial progress, cash runway, and valuation expectations currently line up.

Green Thumb Industries (CNSX:GTII)

Green Thumb Industries brings the Biotech Stocks theme into the cannabis aisle, turning plant based pharmacology into branded medical and adult use products sold through its own dispensaries and wholesale channels across the United States.

Green Thumb Industries generates about US$846 million from Retail and US$681 million from Consumer Packaged Goods, offset by US$318 million of intersegment eliminations, with a total U.S. footprint and a market value around CA$2.4b.

For investors using the Biotech Stocks screener, Green Thumb Industries is the cannabis specialist that links cannabinoid science to a broad product shelf, from flower to vapes to edibles, and then pushes that range through a growing national dispensary network.

"Persistent regulatory uncertainty at the federal and state level, including confusion surrounding the legal status of hemp and cannabis, makes capital allocation decisions difficult and could hinder addressable market expansion, thus restricting revenue growth."

The real swing factor sits in how one unseen pressure on Green Thumb Industries’ future pricing power and margins eventually resolves.

That pressure point is exactly what the full narrative for Green Thumb Industries unpacks, showing how Green Thumb Industries could turn regulatory friction into accelerating brand strength and cash generation potential.

Seeking Fresh Alternatives Before They Fly

New ideas move first. Once the breakout momentum is obvious, the easy entry points are gone and the crowd has already caught on. Scan fresh lists while it matters and get in early.

• Spot cash generative miners before gold chatter hits the headlines by scanning the 36 elite gold producer stocks curated for production strength and balance sheet resilience.
• Track the next wave of electrification demand by running through the 17 top copper producer stocks focused on producers positioned for volume and funding discipline.
• Back test your income watchlist against the 1 dividend fortresses designed to surface higher yield payers with consistent balance sheet support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com